Sapna P. Patel

Jul 4, 2024 | nature.com | Sang T. Kim |Sattva Neelapu |Amishi Y. Shah |Matthew Campbell |don gibbons |Tina Cascone | +10 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-022-29539-3, published online 12 April 2022In this article the funding information for Jordan Kramer was omitted and should have read, ‘J.K. is supported by the CPRIT Research Training Award CPRIT Training Program (RP210028)’. The original article has been corrected.

Aug 17, 2023 | nature.com | Ari Vander Walde |Katie Campbell |Philip O. Scumpia |Alexandra Ikeguchi |Bartosz Chmielowski |Kim Margolin | +3 more

AbstractIn this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone.

Jul 18, 2023 | medscape.com | Sapna P. Patel |Kim Margolin

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Sapna P. Patel, MD: Hello. I'm Dr Sapna Patel. Welcome to Medscape's InDiscussion series on melanoma. This is episode number three.